Meta-analysis of clinical impact of onasemnogene abeparvovec treatment of spinal muscular atrophy patients

被引：0
|
作者：
Reyna, S. [1 ]
Dabbous, O. [1 ]
Wallach, S. [1 ]
Patel, A. [1 ]
Toro, W. [1 ]
Ritter, S. [1 ]
机构：
[1] Novartis Gene Therapies Inc, Bannockburn, IL USA
来源：
NEUROMUSCULAR DISORDERS | 2024年 / 43卷
关键词：
D O I：
10.1016/j.nmd.2024.07.608
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
164P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series
    Chand, Deepa H.
    Zaidman, Craig
    Arya, Kapil
    Millner, Rachel
    Farrar, Michelle A.
    Mackie, Fiona E.
    Goedeker, Natalie L.
    Dharnidharka, Vikas R.
    Dandamudi, Raja
    Reyna, Sandra P.
    JOURNAL OF PEDIATRICS, 2021, 231 : 265 - 268
  • [32] Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec
    Leon-Astudillo, Carmen
    Wagner, Mary
    Salabarria, Stephanie M.
    Lammers, Jenna
    Berthy, Julie
    Zingariello, Carla D.
    Byrne, Barry J.
    Smith, Barbara K.
    SLEEP MEDICINE, 2023, 101 : 234 - 237
  • [33] Onasemnogene abeparvovec in spinal muscular atrophy : predictors of efficacy and safety in naive patients with spinal muscular atrophy and following switch from other therapies
    Pane, Marika
    Berti, Beatrice
    Capasso, Anna
    Coratti, Giorgia
    Varone, Antonio
    D'Amico, Adele
    Messina, Sonia
    Masson, Riccardo
    Sansone, Valeria Ada
    Donati, Maria Alice
    Agosto, Caterina
    Bruno, Claudio
    Ricci, Federica
    Pini, Antonella
    Gagliardi, Delio
    Filosto, Massimiliano
    Corti, Stefania
    Leone, Daniela
    Palermo, Concetta
    Onesimo, Roberta
    De Sanctis, Roberto
    Ricci, Martina
    Bitetti, Ilaria
    Sframeli, Maria
    Dosi, Claudia
    Albamonte, Emilio
    Ticci, Chiara
    Brolatti, Noemi
    Bertini, Enrico
    Finkel, Richard
    Mercuri, Eugenio
    ECLINICALMEDICINE, 2023, 59
  • [34] Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy
    Schwartz, M.
    Likhite, S.
    Meyer, K.
    DRUGS OF TODAY, 2021, 57 (06) : 387 - 399
  • [35] Outcomes of Single-Agent Onasemnogene Abeparvovec or Nusinersen, and of Nusinersen Switching to Onasemnogene Abeparvovec, in Patients With Spinal Muscular Atrophy: Results of a Provider Survey in the United States
    Yang, Min
    Georgieva, Mihaela
    Wu, Eric
    Dabbous, Omar
    LaMarca, Nicole
    Shenouda, Lydia
    Patel, Anish
    Jimenez, Walter Toro
    Bischof, Matthias
    Minkoff, Neil
    NEUROLOGY, 2021, 96 (15)
  • [36] Effect on maximal mouth opening in children with spinal muscular atrophy treated with onasemnogene abeparvovec
    Beri, Nidhi
    Kapoor, Lekha
    Parashar, Deepak
    Mundada, Vivek
    ARCHIVES OF DISEASE IN CHILDHOOD, 2023, 108 (10) : 866 - 867
  • [37] Spinal Muscular Atrophy Patients Treated with Onasemnogene Abeparvovec through a Managed Access Program: A Case Series
    Schultz, M.
    Richardson, R.
    Patterson, K.
    ANNALS OF NEUROLOGY, 2019, 86 : S132 - S133
  • [38] Intravenous (IV) onasemnogene abeparvovec for spinal muscular atrophy (SMA): integrated safety report
    Chand, D.
    Finkel, R.
    Mercuri, E.
    Masson, R.
    Parsons, J.
    Kleyn, A.
    Menier, M.
    Montgomery, K.
    Sproule, D.
    Reyna, S.
    Feltner, D.
    Tauscher-Wisniewki, S.
    Mendell, J.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S120 - S121
  • [39] Onasemnogene abeparvovec AAV vector-based gene-replacement therapy Treatment of spinal muscular atrophy
    Paton, D. M.
    DRUGS OF THE FUTURE, 2019, 44 (08) : 625 - 633
  • [40] Real-world data on the effectiveness and safety of onasemnogene abeparvovec in spinal muscular atrophy
    Weiss, C.
    Becker, L.
    Garbade, S.
    Johannsen, J.
    Ziegler, A.
    NEUROMUSCULAR DISORDERS, 2024, 43
12345